Products for Research Use Only

Alflutinib mesylate

CAT: 0013-GTR19167495-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19167495-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Alflutinib mesylate (AST2818 mesylate) is an irreversible EGFR tyrosine kinase inhibitor with high selectivity for mutant forms, including the T790M resistance mutation. It is utilized in preclinical oncology research, demonstrating activity in both cellular assays and animal models of non-small cell lung cancer.
CAS Number
2130958-55-1
Product Name Alternative
Alflutinib Mesylate, Alflutinib mesylate, Alflutinib, AST 2818, AST 2818 Mesylate, AST2818, AST-2818, AST2818 Mesylate, AST2818 mesylate, AST-2818 Mesylate, cancer, NSCLC, inhibit, Inhibitor, HER1, EGFR, Epidermal growth factor receptor, ErbB-1, Furmonertinib, esistant mutation, T790M
Field of Research
Cardiovascular Research, Signal Transduction
Purity
97.94% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween-80+45% Saline:1 mg/mL (1.5 mM) ; DMSO:55 mg/mL (82.74 mM)
Smiles
CS (O) (=O) =O.CN (C) CCN (C) c1nc (OCC (F) (F) F) c (Nc2nccc (n2) -c2cn (C) c3ccccc23) cc1NC (=O) C=C
Molecular Formula
C29H35F3N8O5S
Molecular Weight
664.70
Storage Conditions
-20°C
Notes
For research use only.

Chemical Information

Alflutinib Mesylate

Alflutinib Mesylate is the mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, alflutinib specifically binds to and inhibits the tyrosine kinase activity of EGFR T790M, a secondarily acquired resistance mutation. This prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Compared to some other EGFR inhibitors, alflutinib may have therapeutic benefits in tumors with T790M-mediated drug resistance.

CAS Number2130958-55-1
PubChem CID134828257
IUPAC NameN-[2-[2-(dimethylamino)ethyl-methylamino]-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]prop-2-enamide;methanesulfonic acid
Molecular FormulaC29H35F3N8O5S
Molecular Weight664.7
Topological Polar Surface Area163
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count14
Rotatable Bond Count11
Heavy Atom Count46
Formal Charge0
Complexity957
SMILES
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(N=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OCC(F)(F)F.CS(=O)(=O)O
InChI
InChI=1S/C28H31F3N8O2.CH4O3S/c1-6-24(40)33-21-15-22(26(41-17-28(29,30)31)36-25(21)38(4)14-13-37(2)3)35-27-32-12-11-20(34-27)19-16-39(5)23-10-8-7-9-18(19)23;1-5(2,3)4/h6-12,15-16H,1,13-14,17H2,2-5H3,(H,33,40)(H,32,34,35);1H3,(H,2,3,4)
InChIKey
WDPGHXINXNBHAS-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Alflutinib Mesylate
CAS: 2130958-55-1
CID: 134828257
Formula: C29H35F3N8O5S
MW: 664.7
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight664.7
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count14
Rotatable Bond Count11
Exact Mass664.24032191
Monoisotopic Mass664.24032191
Topological Polar Surface Area163 Ų
Heavy Atom Count46
Formal Charge0
Complexity957
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count2
Compound Is CanonicalizedYes